Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, 200127, China
NCT Number: NCT07584213
This is a real-world multicentre study to investigate the association between blood routine parameters combined with clinicopathological characteristics and breast cancer prognosis.
This study is active but is not currently recruiting participants.
18 year and older
Female
Observational
Shanghai, 200127, China
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
blood routine test at baseline
Time frame: From the date of radical surgery until time of event up to 3 years
Disease-free survival time is defined as the time from the date of radical surgery until the date of the first occurrence of local/regional relapse, distant recurrence, contralateral breast cancer, second malignancy and death from any cause.
Time frame: From the date of radical surgery until time of event up to 3 years
Recurrence-free survival time is defined as the time from the date of radical surgery until the date of the first occurrence of local/regional recurrence, distant recurrence and death from any cause
Time frame: From the date of radical surgery until time of event up to 3 years
Overall survival time is defined as the time from the date of radical surgery until death from any cause until death from any cause
Wenjin Yin
Other
The Association Between Blood Routine Parameters Combined With Clinicopathological Characteristics and Breast Cancer Prognosis: a Real-world Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07590570
Breast Cancer Invasive
Shanghai, China
View Trial DetailsNCT07283718
Breast Cancer Invasive
Shanghai, China
View Trial DetailsNCT06144944
Breast Cancer Invasive, Breast Diseases
Guangzhou, Guangdong, China
View Trial DetailsNCT06234488
Breast Adenocarcinoma, Breast Cancer
Los Angeles, California, United States
View Trial Details